A comparative study between oral itraconazole and terbinafine in tinea infection

Phase 3

Not yet recruiting

• Conditions: Other specified local infections of the skin and subcutaneous tissue,

• Registration Number: CTRI/2023/10/058844
• Lead Sponsor: Mahatma Gandhi Hospital

Brief Summary

patient will be recruited of tinea infection accroding to inclusion and exclusion criteria and primary outcome will be measured. In this study, efficacy of 130mg SB dose and 200mg dose of itraconazole given once a day and terbinafine 250mg and 500mg given once a day for 6 weeks will be compared. Also the species commonly found in tinea infection and drug and dose most effective against them will be identified.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-10-17
• Study Start: 2023-10-27

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

all KOH positive tinea cases of age between 18 and 65 years -body surface area involvement more than 5% -patient giving written informed consent for study.

Exclusion Criteria

pregnant and lactating women -patient with preexisting renal, hepatic and cardiac disease -patient with onychomycosis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
By assessing dercrease in erythema, scaling, vesiculation, fissuring, maceration, exudation	baseline, 3 weeks, 6 weeks and 12 weeks

Secondary Outcome Measures

Name	Time	Method
to know about relapse	at 3 months follow up

Trial Locations

Locations (1)

Mahatma Gandhi Hospital; 🇮🇳 Jaipur, RAJASTHAN, India

Mahatma Gandhi Hospital

🇮🇳Jaipur, RAJASTHAN, India

Ankita Narola

Principal investigator

9909121207

ankitanarola1@gmail.com